{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T10:57:42Z","timestamp":1775991462790,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T00:00:00Z","timestamp":1752019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100021171","name":"GuangDong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2025A1515012748"],"award-info":[{"award-number":["2025A1515012748"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"President Foundation of Nanfang Hospital, Southern Medical University","award":["2023A036"],"award-info":[{"award-number":["2023A036"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82470214"],"award-info":[{"award-number":["82470214"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["2023YFC2508905"],"award-info":[{"award-number":["2023YFC2508905"]}]},{"name":"National Key Research and Development Program of China","award":["2022YFA11050003"],"award-info":[{"award-number":["2022YFA11050003"]}]},{"name":"Major Program of the National Natural Science Foundation of China","award":["82293634"],"award-info":[{"award-number":["82293634"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Our open-label, multicenter, randomized, phase 3 trial showed that the incidence and severity of chronic graft-versus-host disease (cGVHD) reduced in steroid-resistant acute graft-versus-host disease (aGVHD) patients who underwent mesenchymal stromal cells (MSCs) treatments, but survival benefit was not received. Here, we present a post-hoc analysis of the 5-year follow-up to explore long-term survival and its underlying mechanism.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This long-term follow-up trial included steroid-resistant aGVHD patients, who were randomly assigned (1:1) to receive MSCs (MSC group) (1\u2009\u00d7\u200910<jats:sup>6<\/jats:sup> cells\/kg once weekly for 4 consecutive weeks, 8 doses at most) or without MSCs treatment (control group). For this updated analysis, the 5-year endpoints were cumulative incidence of cGVHD, overall survival, cGVHD-free, relapse-free survival (CRFS), and relapse. To explore the mechanism, We investigated the changes in T, B cells, and signal joint T cell receptor excision DNA circles (sjTRECs).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Between September 2014 and March 2019, 198 patients were randomly assigned to the MSC group (<jats:italic>n<\/jats:italic>\u2009=\u200999) or the control group (<jats:italic>n<\/jats:italic>\u2009=\u200999). Extended follow-up showed the lower 5-year cumulative incidence of cGVHD (42.0% [95%CI 32.2\u201351.5] vs. 67.1% [55.6\u201376.3]; hazard ratio [HR] 2.19, 95%CI 1.47\u20133.27; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001), improved 5-year overall survival (60.4% [50.8\u201370.0] vs. 41.7% [31.9\u201351.5]; 0.63, 0.42\u20130.94; <jats:italic>P<\/jats:italic>\u2009=\u20090.023), CRFS (33.9% [24.5\u201343.3] vs. 20.9% [12.9\u201328.9]; 0.67, 0.48\u20130.93; <jats:italic>P<\/jats:italic>\u2009=\u20090.017) and no increase on relapse (13.6% [7.6\u201321.3] vs. 16.0% [9.5\u201323.9]; 1.24, 0.60\u20132.56; <jats:italic>P<\/jats:italic>\u2009=\u20090.568) for patients in MSC group compared with the control group. Clinical improvement of MSCs was accompanied by significant increases in regulatory T cells, CD4\u2009+\u2009CD45RA\u2009+\u2009CD31\u2009+\u2009na\u00efve T, CD19\u2009+\u2009CD27\u2009+\u2009IgD- memory B cells, and sjTRECs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>With extended follow-up, MSCs reduced the morbidity of cGVHD in aGVHD patients and improved overall survival and CRFS. Mechanistically, MSCs reduced cGVHD by thymus pathway.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>clinicaltrials.gov identifier: NCT02241018. Registration date: 16 September 2014, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02241018\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02241018<\/jats:ext-link>.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s40164-025-00687-8","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T08:46:06Z","timestamp":1752137166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reduced morbidity and mortality of cGVHD in patients who received treatment with mesenchymal stromal cells for steroid-resistant aGVHD: long-term follow-up of a randomized phase 3 trial"],"prefix":"10.1186","volume":"14","author":[{"given":"Ke","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiping","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yonghua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongjun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danian","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AP","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,9]]},"reference":[{"issue":"6","key":"687_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nri3212","volume":"12","author":"BR Blazar","year":"2012","unstructured":"Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol. 2012;12(6):443\u201358.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"687_CR2","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/bmt.2013.107","volume":"49","author":"T Ruutu","year":"2014","unstructured":"Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, et al. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transpl. 2014;49(2):168\u201373.","journal-title":"Bone Marrow Transpl"},{"issue":"22","key":"687_CR3","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMra1609337","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic process, prevention, and therapy. N Engl J Med. 2017;377(22):2167\u201379.","journal-title":"N Engl J Med"},{"issue":"26","key":"687_CR4","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1056\/NEJMra1703472","volume":"377","author":"R Zeiser","year":"2017","unstructured":"Zeiser R, Blazar BR. Pathophysiology of chronic Graft-versus-Host disease and therapeutic targets. N Engl J Med. 2017;377(26):2565\u201379.","journal-title":"N Engl J Med"},{"issue":"1","key":"687_CR5","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40164-022-00350-6","volume":"11","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zhao Y, Qi J, Ma X, Qi X, Wu D, et al. Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD. Exp Hematol Oncol. 2022;11(1):96.","journal-title":"Exp Hematol Oncol"},{"key":"687_CR6","doi-asserted-by":"crossref","unstructured":"Chen Y, Xu Y, Wu D. Advances in graft-versus-host disease prevention strategies: latest updates from the 2022 ASH annual meeting. Exp Hematol Oncol. 2023;12(1):59.","DOI":"10.1186\/s40164-023-00425-y"},{"key":"687_CR7","doi-asserted-by":"publisher","first-page":"217264","DOI":"10.1016\/j.canlet.2024.217264","volume":"605","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chang YJ, Chen J, Han M, Hu J, Hu J, et al. Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic Haematopoietic stem cell transplantation in china: 2024 update. Cancer Lett. 2024;605:217264.","journal-title":"Cancer Lett"},{"issue":"5","key":"687_CR8","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1182\/blood.V97.5.1196","volume":"97","author":"GB Vogelsang","year":"2001","unstructured":"Vogelsang GB. How I treat chronic graft-versus-host disease. Blood. 2001;97(5):1196\u2013201.","journal-title":"Blood"},{"issue":"4","key":"687_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","volume":"9","author":"SJ Lee","year":"2003","unstructured":"Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2003;9(4):215\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12\u2013b Suppl","key":"687_CR10","first-page":"S2","volume":"28","author":"B Flavin","year":"2022","unstructured":"Flavin B. Chronic graft-vs-host disease: current Understanding of disease and treatment landscape. J Manag Care Spec Pharm. 2022;28(12\u2013b Suppl):S2\u201312.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"687_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.4049\/jimmunol.1300657","volume":"191","author":"T Wu","year":"2013","unstructured":"Wu T, Young JS, Johnston H, Ni X, Deng R, Racine J, et al. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4\u2009+\u2009and CD8\u2009+\u2009T cells. J Immunol. 2013;191(1):488\u201399.","journal-title":"J Immunol"},{"issue":"2","key":"687_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.bbmt.2016.09.023","volume":"23","author":"KR Cooke","year":"2017","unstructured":"Cooke KR, Luznik L, Sarantopoulos S, Hakim FT, Jagasia M, Fowler DH, et al. The biology of chronic Graft-versus-Host disease: A task force report from the National institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-Host disease. Biol Blood Marrow Transpl. 2017;23(2):211\u201334.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"687_CR13","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2011-07-364414","volume":"119","author":"M Srinivasan","year":"2012","unstructured":"Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, et al. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012;119(6):1570\u201380.","journal-title":"Blood"},{"issue":"1","key":"687_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40164-022-00286-x","volume":"11","author":"K Lv","year":"2022","unstructured":"Lv K, Hu B, Xu M, Wan L, Jin Z, Xu M, et al. IL-39 promotes chronic graft-versus-host disease by increasing T and B cell pathogenicity. Exp Hematol Oncol. 2022;11(1):34.","journal-title":"Exp Hematol Oncol"},{"issue":"9624","key":"687_CR15","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S0140-6736(08)60690-X","volume":"371","author":"K Le Blanc","year":"2008","unstructured":"Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579\u201386.","journal-title":"Lancet"},{"key":"687_CR16","unstructured":"Bonig H, Kuci Z, Kuci S, Bakhtiar S, Basu O, Bug G et al. Children and adults with refractory acute Graft-versus-Host disease respond to treatment with the mesenchymal stromal cell Preparation MSC-FFM-Outcome report of 92 patients. Cells. 2019;8(12)."},{"issue":"1","key":"687_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-022-01240-4","volume":"15","author":"K Zhao","year":"2022","unstructured":"Zhao K, Lin R, Fan Z, Chen X, Wang Y, Huang F, et al. Mesenchymal stromal cells plus basiliximab, calcineurin inhibitor as treatment of steroid-resistant acute graft-versus-host disease: a multicenter, randomized, phase 3, open-label trial. J Hematol Oncol. 2022;15(1):22.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"687_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.bbmt.2014.09.030","volume":"21","author":"K Zhao","year":"2015","unstructured":"Zhao K, Lou R, Huang F, Peng Y, Jiang Z, Huang K, et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transpl. 2015;21(1):97\u2013104.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"687_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1038\/bmt.2017.35","volume":"52","author":"GM Dotoli","year":"2017","unstructured":"Dotoli GM, De Santis GC, Orellana MD, de Lima Prata K, Caruso SR, Fernandes TR, et al. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III\/IV after hematopoietic stem cell transplantation. Bone Marrow Transpl. 2017;52(6):859\u201362.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"687_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bbmt.2013.11.001","volume":"20","author":"J Kurtzberg","year":"2014","unstructured":"Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, et al. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transpl. 2014;20(2):229\u201335.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"687_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/ejh.12613","volume":"96","author":"LA Kuzmina","year":"2016","unstructured":"Kuzmina LA, Petinati NA, Shipounova IN, Sats NV, Bigildeev AE, Zezina EA, et al. Analysis of multipotent mesenchymal stromal cells used for acute graft-versus-host disease prophylaxis. Eur J Haematol. 2016;96(4):425\u201334.","journal-title":"Eur J Haematol"},{"issue":"12","key":"687_CR22","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1134\/S0006297914120104","volume":"79","author":"IN Shipounova","year":"2014","unstructured":"Shipounova IN, Petinati NA, Bigildeev AE, Zezina EA, Drize NI, Kuzmina LA, et al. Analysis of results of acute graft-versus-host disease prophylaxis with donor multipotent mesenchymal stromal cells in patients with hemoblastoses after allogeneic bone marrow transplantation. Biochem (Mosc). 2014;79(12):1363\u201370.","journal-title":"Biochem (Mosc)"},{"issue":"6","key":"687_CR23","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.bbmt.2010.01.011","volume":"16","author":"F Baron","year":"2010","unstructured":"Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, et al. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol Blood Marrow Transpl. 2010;16(6):838\u201347.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"687_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12916-024-03275-5","volume":"22","author":"H Fu","year":"2024","unstructured":"Fu H, Sun X, Lin R, Wang Y, Xuan L, Yao H, et al. Mesenchymal stromal cells plus Basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial. BMC Med. 2024;22(1):85.","journal-title":"BMC Med"},{"issue":"2","key":"687_CR25","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","volume":"7","author":"O Penack","year":"2020","unstructured":"Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation. Lancet Haematol. 2020;7(2):e157\u201367.","journal-title":"Lancet Haematol"},{"issue":"10","key":"687_CR26","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1002\/sctm.20-0099","volume":"9","author":"E Boberg","year":"2020","unstructured":"Boberg E, von Bahr L, Afram G, Lindstrom C, Ljungman P, Heldring N, et al. Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study. Stem Cells Transl Med. 2020;9(10):1190\u2013202.","journal-title":"Stem Cells Transl Med"},{"issue":"2","key":"687_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1001\/jamaoncol.2023.5757","volume":"10","author":"R Huang","year":"2024","unstructured":"Huang R, Chen T, Wang S, Wang J, Su Y, Liu J, et al. Mesenchymal stem cells for prophylaxis of chronic Graft-vs-Host disease after haploidentical hematopoietic stem cell transplant: an Open-Label randomized clinical trial. JAMA Oncol. 2024;10(2):220\u20136.","journal-title":"JAMA Oncol"},{"issue":"3","key":"687_CR28","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/leu.2014.225","volume":"29","author":"Y Peng","year":"2015","unstructured":"Peng Y, Chen X, Liu Q, Zhang X, Huang K, Liu L, et al. Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5\u2009+\u2009regulatory B cells producing Interleukin 10. Leukemia. 2015;29(3):636\u201346.","journal-title":"Leukemia"},{"issue":"9","key":"687_CR29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.5966\/sctm.2014-0001","volume":"3","author":"Y Peng","year":"2014","unstructured":"Peng Y, Chen X, Liu Q, Xu D, Zheng H, Liu L, et al. Alteration of Naive and memory B-cell subset in chronic graft-versus-host disease patients after treatment with mesenchymal stromal cells. Stem Cells Transl Med. 2014;3(9):1023\u201331.","journal-title":"Stem Cells Transl Med"},{"issue":"24","key":"687_CR30","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1200\/JCO.2015.65.3642","volume":"34","author":"L Gao","year":"2016","unstructured":"Gao L, Zhang Y, Hu B, Liu J, Kong P, Lou S, et al. Phase II multicenter, randomized, Double-Blind controlled study of efficacy and safety of umbilical Cord-Derived mesenchymal stromal cells in the prophylaxis of chronic Graft-Versus-Host disease after HLA-Haploidentical Stem-Cell transplantation. J Clin Oncol. 2016;34(24):2843\u201350.","journal-title":"J Clin Oncol"},{"issue":"1","key":"687_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","volume":"22","author":"AC Harris","year":"2016","unstructured":"Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute Graft-versus-Host disease clinical data collection: A report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transpl. 2016;22(1):4\u201310.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"687_CR32","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","volume":"53","author":"HM Schoemans","year":"2018","unstructured":"Schoemans HM, Lee SJ, Ferrara JL, Wolff D, Levine JE, Schultz KR, et al. EBMT-NIH-CIBMTR task force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transpl. 2018;53(11):1401\u201315.","journal-title":"Bone Marrow Transpl"},{"issue":"19","key":"687_CR33","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","volume":"382","author":"R Zeiser","year":"2020","unstructured":"Zeiser R, von Bubnoff N, Butler J, Mohty M, Niederwieser D, Or R, et al. Ruxolitinib for Glucocorticoid-Refractory acute Graft-versus-Host disease. N Engl J Med. 2020;382(19):1800\u201310.","journal-title":"N Engl J Med"},{"key":"687_CR34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ebiom.2019.09.039","volume":"49","author":"S Chen","year":"2019","unstructured":"Chen S, Zhao K, Lin R, Wang S, Fan Z, Huang F, et al. The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: A multicenter prospective cohort study. EBioMedicine. 2019;49:213\u201322.","journal-title":"EBioMedicine"},{"issue":"3","key":"687_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","volume":"21","author":"MH Jagasia","year":"2015","unstructured":"Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-Host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transpl. 2015;21(3):389\u2013401. e1.","journal-title":"Biol Blood Marrow Transpl"},{"key":"687_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1756-8722-4-19","volume":"4","author":"X Wu","year":"2011","unstructured":"Wu X, Zhu K, Du X, Chen S, Yang L, Wu J, et al. Frequency analysis of TRBV subfamily SjTRECs to characterize T-cell reconstitution in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2011;4:19.","journal-title":"J Hematol Oncol"},{"issue":"27","key":"687_CR37","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36(27):4391\u2013400.","journal-title":"Stat Med"},{"issue":"11","key":"687_CR38","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","volume":"117","author":"ME Flowers","year":"2011","unstructured":"Flowers ME, Inamoto Y, Carpenter PA, Lee SJ, Kiem HP, Petersdorf EW, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National institutes of health consensus criteria. Blood. 2011;117(11):3214\u20139.","journal-title":"Blood"},{"issue":"10","key":"687_CR39","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.bbmt.2016.06.020","volume":"22","author":"M Grube","year":"2016","unstructured":"Grube M, Holler E, Weber D, Holler B, Herr W, Wolff D. Risk factors and outcome of chronic Graft-versus-Host disease after allogeneic stem cell Transplantation-Results from a Single-Center observational study. Biol Blood Marrow Transpl. 2016;22(10):1781\u201391.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"687_CR40","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","volume":"21","author":"S Arai","year":"2015","unstructured":"Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the center for international blood and marrow transplant research. Biol Blood Marrow Transpl. 2015;21(2):266\u201374.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"8","key":"687_CR41","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.bbmt.2012.04.005","volume":"18","author":"PJ Martin","year":"2012","unstructured":"Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American society of blood and marrow transplantation. Biol Blood Marrow Transpl. 2012;18(8):1150\u201363.","journal-title":"Biol Blood Marrow Transpl"},{"key":"687_CR42","doi-asserted-by":"publisher","first-page":"601953","DOI":"10.1155\/2011\/601953","volume":"2011","author":"JR Westin","year":"2011","unstructured":"Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH, et al. Steroid-Refractory acute GVHD: predictors and outcomes. Adv Hematol. 2011;2011:601953.","journal-title":"Adv Hematol"},{"issue":"4A","key":"687_CR43","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/S1083-8791(00)70036-X","volume":"6","author":"L Cragg","year":"2000","unstructured":"Cragg L, Blazar BR, Defor T, Kolatker N, Miller W, Kersey J, et al. A randomized trial comparing prednisone with antithymocyte globulin\/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transpl. 2000;6(4A):441\u20137.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"687_CR44","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.bbmt.2018.11.017","volume":"25","author":"M Faraci","year":"2019","unstructured":"Faraci M, Calevo MG, Giardino S, Leoni M, Ricci E, Castagnola E, et al. Etanercept as treatment of Steroid-Refractory acute Graft-versus-Host disease in pediatric patients. Biol Blood Marrow Transpl. 2019;25(4):743\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"687_CR45","doi-asserted-by":"publisher","first-page":"2865","DOI":"10.1007\/s00277-023-05361-9","volume":"102","author":"J Liu","year":"2023","unstructured":"Liu J, Fan Z, Xu N, Ye J, Chen Y, Shao R, et al. Ruxolitinib versus Basiliximab for steroid-refractory acute graft-versus-host disease: a retrospective study. Ann Hematol. 2023;102(10):2865\u201377.","journal-title":"Ann Hematol"},{"issue":"7","key":"687_CR46","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41409-020-0834-4","volume":"55","author":"IS Moiseev","year":"2020","unstructured":"Moiseev IS, Morozova EV, Bykova TA, Paina OV, Smirnova AG, Dotsenko AA, et al. Long-term outcomes of ruxolitinib therapy in steroid-refractory graft-versus-host disease in children and adults. Bone Marrow Transpl. 2020;55(7):1379\u201387.","journal-title":"Bone Marrow Transpl"},{"issue":"18","key":"687_CR47","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1182\/bloodadvances.2022009646","volume":"7","author":"X Zhang","year":"2023","unstructured":"Zhang X, He J, Zhao K, Liu S, Xuan L, Chen S, et al. Mesenchymal stromal cells ameliorate chronic GVHD by boosting thymic regeneration in a CCR9-dependent manner in mice. Blood Adv. 2023;7(18):5359\u201373.","journal-title":"Blood Adv"},{"key":"687_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.fob.2012.07.003","volume":"2","author":"S Lax","year":"2012","unstructured":"Lax S, Ross EA, White A, Marshall JL, Jenkinson WE, Isacke CM, et al. CD248 expression on mesenchymal stromal cells is required for post-natal and infection-dependent thymus remodelling and regeneration. FEBS Open Bio. 2012;2:187\u201390.","journal-title":"FEBS Open Bio"},{"issue":"9","key":"687_CR49","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.intimp.2011.04.006","volume":"11","author":"KX Hu","year":"2011","unstructured":"Hu KX, Wang MH, Fan C, Wang L, Guo M, Ai HS. CM-DiI labeled mesenchymal stem cells homed to thymus inducing immune recovery of mice after haploidentical bone marrow transplantation. Int Immunopharmacol. 2011;11(9):1265\u201370.","journal-title":"Int Immunopharmacol"},{"issue":"9218","key":"687_CR50","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/S0140-6736(00)02293-5","volume":"355","author":"DC Douek","year":"2000","unstructured":"Douek DC, Vescio RA, Betts MR, Brenchley JM, Hill BJ, Zhang L, et al. Assessment of thymic output in adults after Haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet. 2000;355(9218):1875\u201381.","journal-title":"Lancet"},{"issue":"11","key":"687_CR51","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1002\/eji.200636976","volume":"37","author":"S Junge","year":"2007","unstructured":"Junge S, Kloeckener-Gruissem B, Zufferey R, Keisker A, Salgo B, Fauchere JC, et al. Correlation between recent thymic emigrants and CD31+ (PECAM-1) CD4\u2009+\u2009T cells in normal individuals during aging and in lymphopenic children. Eur J Immunol. 2007;37(11):3270\u201380.","journal-title":"Eur J Immunol"},{"issue":"3","key":"687_CR52","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.4049\/jimmunol.180.3.1499","volume":"180","author":"RD Kilpatrick","year":"2008","unstructured":"Kilpatrick RD, Rickabaugh T, Hultin LE, Hultin P, Hausner MA, Detels R, et al. Homeostasis of the Naive CD4\u2009+\u2009T cell compartment during aging. J Immunol. 2008;180(3):1499\u2013507.","journal-title":"J Immunol"},{"issue":"8","key":"687_CR53","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1182\/blood-2005-03-1257","volume":"106","author":"E Zorn","year":"2005","unstructured":"Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency of FOXP3\u2009+\u2009CD4\u2009+\u2009CD25\u2009+\u2009regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005;106(8):2903\u201311.","journal-title":"Blood"},{"issue":"7","key":"687_CR54","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1182\/blood-2004-03-1040","volume":"104","author":"Y Miura","year":"2004","unstructured":"Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, et al. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood. 2004;104(7):2187\u201393.","journal-title":"Blood"},{"issue":"2","key":"687_CR55","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.bbmt.2007.10.009","volume":"14","author":"HT Greinix","year":"2008","unstructured":"Greinix HT, Pohlreich D, Kouba M, Kormoczi U, Lohmann I, Feldmann K, et al. Elevated numbers of immature\/transitional CD21- B lymphocytes and deficiency of memory CD27\u2009+\u2009B cells identify patients with active chronic graft-versus-host disease. Biol Blood Marrow Transpl. 2008;14(2):208\u201319.","journal-title":"Biol Blood Marrow Transpl"},{"key":"687_CR56","doi-asserted-by":"publisher","first-page":"100249","DOI":"10.1016\/j.eclinm.2019.100249","volume":"19","author":"M Thompson","year":"2020","unstructured":"Thompson M, Mei SHJ, Wolfe D, Champagne J, Fergusson D, Stewart DJ, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;19:100249.","journal-title":"EClinicalMedicine"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00687-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00687-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00687-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:32:25Z","timestamp":1752139945000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00687-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,9]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["687"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00687-8","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,9]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Declaration of Helsinki principles. All procedures involving human subjects were approved by the Nanfang Hospital of Southern Medical University Review Board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"95"}}